Experimental drug prolongs survival, improves muscle function in mice severe Duchenne muscular dystrophy

Researchers at Johns Hopkins Medicine report that an experimental drug first developed to treat kidney disease prolongs survival and improves muscle function in mice genetically engineered to develop a severe form of Duchenne muscular dystrophy (DMD).

Related Keywords

Ridgefield ,Connecticut ,United States ,William Jeffreys ,Bryan Riddle ,Steven Pullen ,Brian Lin ,David Kass ,Emily Henderson ,Christopher Ward ,Esteban Velarde ,Nadan Wang ,Antonio Filareto ,Olivia Hanselman ,Seoyoung Kwon ,Megan Moorer ,Joseph Shin ,Suraj Kannan ,Johns Hopkins University ,Boehringer Ingelheim Pharmaceuticals In Ridgefield ,Muscular Dystrophy Association ,University Of Maryland ,Johns Hopkins University School Of Medicine ,Boehringer Ingelheim Pharmaceuticals ,Johns Hopkins Medicine ,Clinical Investigation ,Virginia Weiss Professor ,Johns Hopkins University School ,Clarisse Lukban ,Duchenne Muscular Dystrophy ,Son ,Ton Channel ,Muscle ,Muscular Dystrophy ,One ,Calcium ,Fell ,Dystrophin ,Gene ,Enetic ,Genetic Disorder ,Heart ,Kidney ,Kidney Disease ,Life Expectancy ,Medicine ,Muscle Wasting ,Pharmaceuticals ,Placebo ,Protein ,Research ,